Search research articles
Contact Us
Filters
Showing results (161-170 of 247) with videos related to
Page
of 25
Sort By:
Internal Medicine Journal
|
March 1, 2012
Method for identifying eligible individuals for a prevalence survey in the absence of a disease register or population register
A K Richardson, G Clarke, C E Sabel, et al.
Histopathology
|
March 3, 2015
Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients
Zac Gerring, John F Pearson, Helen R Morrin, et al.
Brain : a Journal of Neurology
|
March 11, 2021
The latitude gradient for multiple sclerosis prevalence is established in the early life course
Clive E Sabel, John F Pearson, Deborah F Mason, et al.
The Biochemical Journal
|
January 22, 2000
Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells
R M Hill, P K Parmar, L C Coates, et al.
Internal Medicine Journal
|
November 10, 2018
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre
Barry D Hock, Katie S Mulholland, Peter Ganly, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 4, 2010
MS prevalence in New Zealand, an ethnically and latitudinally diverse country
Bruce V Taylor, John F Pearson, Glynnis Clarke, et al.
Internal Medicine Journal
|
September 25, 2016
Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients
B D Hock, N D McIntosh, J L McKenzie, et al.
Scientific Reports
|
March 31, 2021
Variable expression quantitative trait loci analysis of breast cancer risk variants
George A R Wiggins, Michael A Black, Anita Dunbier, et al.
Plos One
|
September 15, 2023
Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
Barry D Hock, Liping Goddard, Sean A MacPherson, et al.
Frontiers in Oncology
|
May 19, 2018
Investigation of Experimental Factors That Underlie <i>BRCA1/2</i> mRNA Isoform Expression Variation: Recommendations for Utilizing Targeted RNA Sequencing to Evaluate Potential Spliceogenic Variants
Vanessa L Lattimore, John F Pearson, Margaret J Currie, et al.
Page
of 25
Search research articles
Search
Showing results (161-170 of 247) with videos related to
Sort By:
Page
of 25
Internal Medicine Journal
|
March 1, 2012
Method for identifying eligible individuals for a prevalence survey in the absence of a disease register or population register
A K Richardson, G Clarke, C E Sabel, et al.
Histopathology
|
March 3, 2015
Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients
Zac Gerring, John F Pearson, Helen R Morrin, et al.
Brain : a Journal of Neurology
|
March 11, 2021
The latitude gradient for multiple sclerosis prevalence is established in the early life course
Clive E Sabel, John F Pearson, Deborah F Mason, et al.
The Biochemical Journal
|
January 22, 2000
Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells
R M Hill, P K Parmar, L C Coates, et al.
Internal Medicine Journal
|
November 10, 2018
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre
Barry D Hock, Katie S Mulholland, Peter Ganly, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 4, 2010
MS prevalence in New Zealand, an ethnically and latitudinally diverse country
Bruce V Taylor, John F Pearson, Glynnis Clarke, et al.
Internal Medicine Journal
|
September 25, 2016
Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients
B D Hock, N D McIntosh, J L McKenzie, et al.
Scientific Reports
|
March 31, 2021
Variable expression quantitative trait loci analysis of breast cancer risk variants
George A R Wiggins, Michael A Black, Anita Dunbier, et al.
Plos One
|
September 15, 2023
Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab
Barry D Hock, Liping Goddard, Sean A MacPherson, et al.
Frontiers in Oncology
|
May 19, 2018
Investigation of Experimental Factors That Underlie <i>BRCA1/2</i> mRNA Isoform Expression Variation: Recommendations for Utilizing Targeted RNA Sequencing to Evaluate Potential Spliceogenic Variants
Vanessa L Lattimore, John F Pearson, Margaret J Currie, et al.
Page
of 25